Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Date:6/3/2008

protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the Phase 1 and Phase 2 clinical trials for KRX-0401; we may not be able to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 Valeant Pharmaceuticals International, ... today announced the expiration of the tender offer (the ... to purchase all of the outstanding shares of Salix ... price of $173.00 per share in cash, without interest, ... midnight, Eastern time, on April 1, 2015.  Valeant expects ...
(Date:4/1/2015)... Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: ... raw materials used in the manufacture of traditional Chinese medicine ... financial results for the three- and twelve-months ended December 31, ... 31,Twelve Months Ended December 31, 2014 , 2013 ... $686,669 , $998,934 $4,043,290 , ...
(Date:3/31/2015)... March 31, 2015 Neurocrine Biosciences, Inc. (Nasdaq: ... into an exclusive collaboration and licensing agreement for the ... Japan and other select Asian ... Tanabe intends to initially develop NBI-98854 in ... disease and tardive dyskinesia. Neurocrine retains full commercial rights ...
Breaking Medicine Technology:Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 2Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 4Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 5Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 6Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 7Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 8Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 9Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 10Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 11Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:4/1/2015)... 01, 2015 With so much wet weather ... spend much of their time indoors. When all this time ... air. The latest article from Clean Crawls offers ... in their homes. , One of the ways to ... to keep houseplants. The article states that, “Toluene, Xylene, and ...
(Date:4/1/2015)... Amercanex Corporation, today announced that Native ... Exchange and will conduct its wholesale business thru Amercanex ... exchange as one of the oldest and largest dispensaries ... stores in 9 locations with plans of expansion to ... excited to have Native Roots join Amercanex as they ...
(Date:4/1/2015)... 2015 Phybridge Inc., a provider ... today its strategic partnership with SaskTel in a ... the businesses of Saskatchewan. SaskTels’ Integrated Business Communications ... that offers users a hosted IP unified communications ... The objective of IBC is to offer an ...
(Date:4/1/2015)... 01, 2015 Eighty seven high schools ... from California Casualty . Many of the schools ... and subsequently have fewer and fewer dollars allocated to ... Casualty Chairman Emeritus Thomas R. Brown, who recognized that ... classroom. Since its inception in 2011, over $400,000 ...
(Date:4/1/2015)... "Giving credit where credit is due ... are inestimable." - Loretta Young , The American Water ... resources profession. The Call for Nominations for our ... a colleague, or organization for one of these awards. ... the AWRA Awards and view the nomination criteria and ...
Breaking Medicine News(10 mins):Health News:3 Simple Ways to Improve Home Air Quality Listed by Clean Crawls in Latest Article 2Health News:Amercanex, Native Roots form Exclusive Relationship to facilitate Wholesale Business 2Health News:Amercanex, Native Roots form Exclusive Relationship to facilitate Wholesale Business 3Health News:Phybridge and SaskTel Team Up to Eliminate Network Barriers for IP Telephony and Unified Communications Migration 2Health News:Phybridge and SaskTel Team Up to Eliminate Network Barriers for IP Telephony and Unified Communications Migration 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 4Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 5Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 3
... as the third leading cause of death among adolescents ... (DU) study reveals inhaling or huffing vapors of common ... associated with increased suicidal thoughts and attempts. , Of ... solvents, 25 percent had attempted suicide, and 58 percent ...
... Times, Optimize Planning, Objectives and Offer Increased Clinical ... 29 Accuray,Incorporated (Nasdaq: ARAY ), a ... four new products designed to improve treatment times,optimize ... radiation delivery. These products are being launched at ...
... ... Healthcare Provider Earns $1.6 Million in Rebates This Year, Highlights ... Redwood City Project, ... the nation,s largest not-for-profit,health plan, will today celebrate significant energy efficiency upgrades,and solar ...
... quarter includes $1.8 million of first year milestone ... DUBLIN, Calif., Oct. 29 SuperGen Inc.,(Nasdaq: SUPG ... and commercialization of therapies for solid tumors and,hematological malignancies, ... months ended September 30, 2007. The Company reported ...
... are lots of other reasons to avoid the habit, experts ... be unhealthy in many other ways, but smoking does not ... cancer will have more aggressive or later-stage malignancy at the ... an analysis of data gathered on more than 6,000 women ...
... to Detect, Diagnose and,Personalize Treatment, WHAT: AdvaMed is holding a briefing ... media on the importance of molecular diagnostics in addressing ... community., ... African-Americans that, if caught earlier and managed more ...
Cached Medicine News:Health News:Study reveals 'huffing' household chemicals connected to teen suicide 2Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 2Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 4Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 5Health News:The Healing Power of Green 2Health News:The Healing Power of Green 3Health News:SuperGen Reports 2007 Third Quarter Financial Results 2Health News:SuperGen Reports 2007 Third Quarter Financial Results 3Health News:SuperGen Reports 2007 Third Quarter Financial Results 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 5Health News:SuperGen Reports 2007 Third Quarter Financial Results 6Health News:SuperGen Reports 2007 Third Quarter Financial Results 7Health News:SuperGen Reports 2007 Third Quarter Financial Results 8Health News:SuperGen Reports 2007 Third Quarter Financial Results 9Health News:SuperGen Reports 2007 Third Quarter Financial Results 10Health News:Smoking Does Not Worsen Breast Cancer 2Health News:Smoking Does Not Worsen Breast Cancer 3Health News:AdvaMed Convenes Panel to Address Health Disparities 2
... Penilab IV and the Penilab V have an exceptionally ... 1060 is similar to the Model 1061 shown below, ... be added later. The Penilab V has a ... the accessories you'll need to get started. Latex ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... MRI-Compatible Anesthesia System is perfect for larger surgery ... type of anesthetic agent. , ,The Integra ... its wider stance, has a larger work area. ... is utilized in both the Integra I and ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
Medicine Products: